We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.00 | 34.85 | 35.20 | 35.10 | 34.25 | 35.00 | 391,646 | 10:21:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 205.88 | 189.05M |
TIDMAPH
RNS Number : 7891I
Alliance Pharma PLC
21 June 2017
For immediate release 21 June 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Application for block admission
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has today applied for a block admission for a further 25,000,000 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM (the "Block Admission"). The Block Admission will be used to facilitate the admission of shares to trading following the exercise of options granted under the following employee share schemes:
-- The Alliance Pharma plc Approved Share Option Plan 2005 (up to 2,248,922 shares);
-- The Alliance Pharma plc Share Option Plan 2006 (up to 19,461,225 shares); and
-- The Alliance Pharma plc Company Share Option Plan 2015 (up to 3,289,853 shares).
It is expected that the Block Admission will become effective in the Ordinary Shares on 28 June 2017.
The Company will make six-monthly announcements of the utilisation of the Block Admission, in line with its obligations under AIM Rule 29.
New Ordinary Shares issued following option exercises and admitted to trading under the Block Admission will rank pari passu in all respects with the existing Ordinary Shares.
At the time of this application, Alliance has 474,307,589 Ordinary Shares in issue.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966 John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer Rob Bellhouse, Company Secretary www.alliancepharma.co.uk + 44 (0) 20 7466 Buchanan 5000 Mark Court / Sophie Cowles + 44 (0) 20 7260 Numis Securities Limited 1000 Nominated Adviser: Michael Meade / Freddie Barnfield Corporate Broking: James Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSFBMJTMBATBMR
(END) Dow Jones Newswires
June 21, 2017 09:53 ET (13:53 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions